TY - JOUR
T1 - Involvement of the extracellular signal-regulated protein kinase (ERK) pathway in the induction of apoptosis by cadmium chloride in CCRF-CEM cells
AU - Iryo, Yoshihisa
AU - Matsuoka, Masato
AU - Wispriyono, Bambang
AU - Sugiura, Tsutomu
AU - Igisu, Hideki
N1 - Funding Information:
This work was supported, in part, by a fund from the Health Science Center Foundation, and a Special Research Grant from the University of Occupational and Environmental Health, Japan.
PY - 2000/12/15
Y1 - 2000/12/15
N2 - When CCRF-CEM cells were incubated with 5-40 μM CdCl2, apoptosis was observed most clearly at 10 μM. Prior to the development of apoptosis, mitogen-activated protein kinases (MAPKs), i.e. extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, were activated with different sensitivity to CdCl2 exposure. ERK and p38 MAPK were phosphorylated with incubation of 1 μM CdCl2, but higher than 20 μM CdCl2 was required for the clear phosphorylation of JNK. In the time-course study, ERK and p38 MAPK were phosphorylated earlier than JNK after CdCl2 exposure. The in vitro activities of MAPKs also increased in response to CdCl2 exposure. Pretreatment with an intracellular Ca2+ chelator, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA/AM), suppressed almost completely CdCl2-induced phosphorylation of JNK and p38 MAPK, but not ERK phosphorylation, indicating that the activation of JNK and p38 MAPK depends on the intracellular Ca2+ but that of ERK does not. On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), suppressed CdCl2-induced ERK activation and the apoptosis as well. The inhibition of p38 MAPK activity with SB203580 (4-[4-fluorophenyl]-2-[4-methylsulfinylphenyl]-5-[4-pyridyl]1H-im idazole) did not protect cells from apoptosis. The present results showed that the activation of ERK, JNK, and p38 MAPK is differently regulated in CCRF-CEM cells exposed to CdCl2, and that the ERK pathway seems to be responsible for the induction of apoptosis by CdCl2 exposure in this human T cell line. (C) 2000 Elsevier Science Inc.
AB - When CCRF-CEM cells were incubated with 5-40 μM CdCl2, apoptosis was observed most clearly at 10 μM. Prior to the development of apoptosis, mitogen-activated protein kinases (MAPKs), i.e. extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, were activated with different sensitivity to CdCl2 exposure. ERK and p38 MAPK were phosphorylated with incubation of 1 μM CdCl2, but higher than 20 μM CdCl2 was required for the clear phosphorylation of JNK. In the time-course study, ERK and p38 MAPK were phosphorylated earlier than JNK after CdCl2 exposure. The in vitro activities of MAPKs also increased in response to CdCl2 exposure. Pretreatment with an intracellular Ca2+ chelator, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA/AM), suppressed almost completely CdCl2-induced phosphorylation of JNK and p38 MAPK, but not ERK phosphorylation, indicating that the activation of JNK and p38 MAPK depends on the intracellular Ca2+ but that of ERK does not. On the other hand, treatment with a MAPK/ERK kinase (MEK) inhibitor, U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene), suppressed CdCl2-induced ERK activation and the apoptosis as well. The inhibition of p38 MAPK activity with SB203580 (4-[4-fluorophenyl]-2-[4-methylsulfinylphenyl]-5-[4-pyridyl]1H-im idazole) did not protect cells from apoptosis. The present results showed that the activation of ERK, JNK, and p38 MAPK is differently regulated in CCRF-CEM cells exposed to CdCl2, and that the ERK pathway seems to be responsible for the induction of apoptosis by CdCl2 exposure in this human T cell line. (C) 2000 Elsevier Science Inc.
KW - Apoptosis
KW - CCRF-CEM cells
KW - Cadmium
KW - ERK
KW - JNK
KW - P38 MAPK
UR - http://www.scopus.com/inward/record.url?scp=0034672641&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(00)00510-4
DO - 10.1016/S0006-2952(00)00510-4
M3 - Article
C2 - 11108803
AN - SCOPUS:0034672641
SN - 0006-2952
VL - 60
SP - 1875
EP - 1882
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 12
ER -